Compare MCHP & GEHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MCHP | GEHC |
|---|---|---|
| Founded | 1989 | 1892 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Computer Software: Prepackaged Software |
| Sector | Technology | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.7B | 37.0B |
| IPO Year | 2004 | 2022 |
| Metric | MCHP | GEHC |
|---|---|---|
| Price | $61.74 | $82.91 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 26 | 22 |
| Target Price | $86.48 | ★ $87.85 |
| AVG Volume (30 Days) | ★ 14.4M | 4.1M |
| Earning Date | 11-05-2026 | 10-28-2026 |
| Dividend Yield | ★ 2.93% | 0.20% |
| EPS Growth | ★ 2300.00 | 4.84 |
| EPS | 1.05 | ★ 3.44 |
| Revenue | $5,349,500,000.00 | ★ $20,625,000,000.00 |
| Revenue This Year | $35.45 | $6.01 |
| Revenue Next Year | $15.62 | $4.87 |
| P/E Ratio | $59.03 | ★ $23.83 |
| Revenue Growth | ★ 34.38 | 4.84 |
| 52 Week Low | $48.52 | $58.75 |
| 52 Week High | $105.91 | $89.77 |
| Indicator | MCHP | GEHC |
|---|---|---|
| Relative Strength Index (RSI) | 35.73 | 68.64 |
| Support Level | $58.51 | $60.90 |
| Resistance Level | $83.27 | $86.56 |
| Average True Range (ATR) | 4.64 | 2.37 |
| MACD | -1.49 | 0.22 |
| Stochastic Oscillator | 25.81 | 74.18 |
Microchip Technology became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (15%), and pharmaceutical diagnostics (14%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 11%, and 17%, respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one-third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).